Skip to content
naulon
Not checkedNot checked for notices yet.

Anti‐Inflammatory Peptides as Promising Therapeutics Agent Against Inflammatory Bowel Diseases: A Systematic Review

Kiarash Ghazvini, Zahra Taghiabadi, Mohammad Ali Karimi and 3 more

JGH Open · 2025

doi:10.1002/jgh3.70212 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

ABSTRACT Background Inflammatory bowel disease (IBD) is linked to dysregulated mucosal immunity, microbiota imbalances, and environmental factors, though its exact cause remains unknown. Current treatments often have limitations, necessitating innovative therapies. This review evaluates anti‐inflammatory peptides (AIPs) as emerging therapeutic agents, focusing on their efficacy in Ulcerative Colitis and Crohn's disease. Methodology A systematic review was conducted in February 2023, adhering to PRISMA 2020 guidelines. Studies published from 2010 to 2023 on AIPs for IBD treatment were retrieved from Medline, Web of Science, and Cochrane databases using keywords such as IBDs, AIPs, Crohn's disease, Ulcerative Colitis, and therapy. Results Seventeen studies met the inclusion criteria, comprising 12 animal studies, four clinical trials, and one case–control study. H‐SN1 (snake venom peptide) and GLP‐2② (glucagon‐like peptide‐2 dimer) effectively inhibited TNF cytotoxicity. Oral AVX‐470 (bovine‐derived anti‐TNF antibody) reduced enterocyte TNF, MPO, and apoptosis levels. Ac2‐26 (annexin A1 mimic) and αs2‐casein peptide combined with synbiotics were shown to restore gut homeostasis and dysbiosis. AMP‐18 (gastrokine‐1) and MBCP (buffalo milk peptide) stabilized tight junctions, preserving intestinal barrier integrity and potentially preventing IBD progression. Conclusion AIPs effectively reduce inflammation, regulate gut microbiota, and stabilize the intestinal barrier, showing promise for managing IBD. However, their therapeutic potential is limited by protease degradation, poor bioavailability, and possible cytotoxicity. Future research should enhance their stability, delivery systems, and pharmacokinetic properties to optimize their clinical applicability and safety.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.